In the last trading session, 2.9 million shares of the Cabaletta Bio Inc (NASDAQ:CABA) were traded, and its beta was 2.79. Most recently the company’s share price was $1.93, and it changed around -$0.06 or -2.76% from the last close, which brings the market valuation of the company to $98.19M. CABA currently trades at a discount to its 52-week high of $13.50, offering almost -599.48% off that amount. The share price’s 52-week low was $0.99, which indicates that the current value has risen by an impressive 48.7% since then.
Cabaletta Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.36. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended CABA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Cabaletta Bio Inc is expected to report earnings per share of -0.61 for the current quarter.
Cabaletta Bio Inc (NASDAQ:CABA) trade information
Instantly CABA has showed a red trend with a performance of -2.76% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.5450 on recent trading dayincreased the stock’s daily price by 24.17%. The company’s shares are currently down -14.76% year-to-date, but still down -18.35% over the last five days. On the other hand, Cabaletta Bio Inc (NASDAQ:CABA) is 6.91% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 86.21% from its current value. Analyst projections state that CABA is forecast to be at a low of $3 and a high of $32.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 4.17M in revenue for the current quarter. 6 analysts expect Cabaletta Bio Inc to make 833.33k in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -20.35%. Cabaletta Bio Inc earnings are expected to increase by -5.45% in 2025, but the outlook is positive 3.54% per year for the next five years.
CABA Dividends
Cabaletta Bio Inc’s next quarterly earnings report is expected to be released in July.
BLACKROCK INC., with 9.6469% or 4.76 million shares worth $35.58 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
